Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
2 December 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug application of Heparin Sodium Injection (the "**Drug**") submitted by Suzhou Erye Pharmaceutical Co., Ltd.* (蘇州二葉製藥有限公司, the "**Suzhou Erye**"), being a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司), was accepted by the National Medical Products Administration.

II. General information and research progress of the Drug

The Drug is a chemical drug independently developed by the Group (i.e., the Company and its subsidiaries/units, the same hereinafter), which is intended to be used for (1) prevention and treatment of venous thrombosis and pulmonary embolism, (2) prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgeries or otherwise at risk for thromboembolic diseases, (3) treatment of atrial fibrillation with embolisation, (4) treatment of acute and chronic consumptive coagulopathy (disseminated intravascular coagulation), (5) prevention of blood coagulation in arterial and cardiac surgeries, (6) prevention and treatment of peripheral arterial embolism, and (7) anticoagulants for transfusion, extracorporeal circulation and dialysis.

As of October 2025, Suzhou Erye has invested approximately RMB8.61 million (unaudited) in total in the research and development of the Drug at the current stage.

According to the latest data of IQVIA CHPA[1], the sales of Heparin Sodium Injections in China in 2024 was approximately RMB1,386 million.

III. Impact on the Listed Company and Risk Warning

The Drug is subject to, among others, the obtaining of drug registration approval before its commercial production. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of the pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
2 December 2025

**For identification purpose only*

[1] provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China; the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.